Creo Pharma Ltd.
Creo Pharma Ltd., a marketer and distributor of generic pharmaceuticals in the United Kingdom, is focused on the commercial pharmaceutical arena, providing alternative brands and generics to fill open prescriptions; supplying specific unlicensed and products direct-to-retail and hospital pharmacy; and providing an after-hours emergency service for the supply of critical medicine.
Amneal and Creo Pharma is a formidable and flexible team dedicated to providing unparalleled quality and service to its customers and suppliers. Access to the European market allows Amneal to expand its product pipeline and offer its customers an ever-expanding range of innovative medicines and specialty generics.
In 2014, Amneal purchased Bioeq Pharma GmbH to provide generic products for the German pharmaceutical market. Patients, pharmacists and physicians can expect the same quality, reliability and service that has helped shape Amneal’s reputation worldwide.
Amneal Ireland Limited is located on Cahir Road in Cashel, County Tipperary. The facility will be dedicated to the production of metered dose (MDI) and dry powder (DPI) inhalers.
Amneal chose Cashel not only for its excellent existing infrastructure, but also for the quality of its local workforce, the enthusiastic support of government leaders, and a positive business environment. The company in turn brings to Cashel a proven track record of providing steady jobs, empowering employees to do their best work, and collaborating with the surrounding community to build a superb operation, aligned with Amneal’s core values.
If you are interested in a job with Amneal Ireland, please send your resume or CV to email@example.com.
The company’s expanding operations in India are an integral part of Amneal’s R&D and manufacturing capabilities and expertise. Its active pharmaceutical ingredient (API) operations allow complete vertical integration of a portion of Amneal’s product portfolio.
These facilities have state-of-the-art infrastructure and are staffed with expert scientific teams developing complex chemistries and numerous classes of compounds that are in compliance to U.S. FDA standards. As a result, Amneal enjoys the flexibility to support several first-to-market and first-to-file opportunities in which possible API scarcity or complexity might otherwise pose a barrier to entry.